Oncimmune signs new master service agreement with Augmenta

Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced that it has signed a new master service agreement with Augmenta Bioworks, Inc. to profile patient plasma samples and characterise therapeutic candidates discovered through Augmenta’s SingleCyte® and DeepGridTM discovery platforms.

Augmenta is a California-based biotech company which works with leading pharmaceutical companies, biotechnology companies, and research institutions to discover new therapies by identifying the human immune system’s protective response to diseases.

The first project to be undertaken under this agreement will utilise Oncimmune’s oncology SeroTagTM technology to identify specific therapeutic antibodies that bind to human antigens found in cancer patients. This analysis will provide insight into clinical efficacy as well as off-target and non-specific binding as an indicator, for example, for adverse events.

Furthermore, under the agreement, an option exists to substantially increase the number of samples analysed and to run these samples over Oncimmune’s infectious disease panel. On 6 October 2020, we announced Oncimmune’s participation in the IMmunity Profiling of pAtients with COVID-19 for Therapy and Triage (“IMPACTT”) programme to develop and validate an Infectious Disease NavigAID™ panel designed to predict COVID-19 disease severity and therapeutic response.

Christopher J Emig, PhD, CEO of Augmenta said: “We are looking forward to uncovering novel therapeutic candidates through the combination of Oncimmune’s biomarker platform and Augmenta’s massively scalable single cell analysis technologies.  Additionally, the data from this project will serve to further demonstrate the superior features of our monoclonal antibodies currently in development.”

Adam M Hill, CEO of Oncimmune said: “We are delighted to be partnering with such a progressive and respected organisation as Augmenta on this important programme. Oncimmune’s proven SeroTag proprietary biomarker discovery engine is ideally suited to this project. We are also excited about the prospect of, once again, utilising our infectious diseases panel to help support the fight against COVID-19.”

Click to view all articles for the EPIC: ,
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn

    More articles like this

    Fintel plc

    Fintel core revenue growth is higher than Zeus forecast

    Fintel plc (LON:FNTL), the leading provider of Fintech and support services to the UK retail financial services sector, has released a trading update for the six months to 30 June 2022, which reveals: Core revenue grew

    OnTheMarket Plc

    OnTheMarket analyst Zeus confident in forecasts

    Foxtons, one of London’s leading estate agencies with more than 50 interconnected branches across London, has signed an agreement to advertise its UK residential sales and letting properties at OnTheMarket plc (LON:OTMP). Zeus view: Foxtons, the

    SpaceandPeople analyst Zeus restores estimates and valuation

    SpaceandPeople plc (LON:SAL) secures, sells, and manages flexible space for brand experiences, short term promotions and retailing in high footfall venues for its customers, including in shopping centres and travel hubs. The Group has issued a

    Lookers Plc

    Lookers shares are still undervalued says Zeus

    Lookers plc (LON:LOOK) has released an H1 trading update reporting a continuation of strong performance year to date. H1 2022 underlying PBT is expected to be c. £45m and Management anticipate full year PBT will also

    Inchcape

    Inchcape performance exceeding expectations says Zeus

    Inchcape plc (LON:INCH) has released another positive trading update, with performance exceeding expectations so far this year. This follows on from a positive Q1 update on 28 April. Through quarterly improvement in Distribution volumes and operating

    boohoo Plc

    Boohoo Group analyst Zeus sees a strong performance in Q1

    ¨ Q1 financial highlights: Boohoo Group plc (LON:BOO) revenue of £445.7m is -8.3% YOY vs. a strong comp (Q1 FY22 revenue +32.1%), in line with Zeus’s forecast and management’s previously stated guidance. Gross sales growth remained